Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54.7M
-
Number of holders
-
104
-
Total 13F shares, excl. options
-
44.7M
-
Shares change
-
+3.56M
-
Total reported value, excl. options
-
$485M
-
Value change
-
+$47.9M
-
Put/Call ratio
-
0.19
-
Number of buys
-
64
-
Number of sells
-
-49
-
Price
-
$10.86
Significant Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q2 2023
142 filings reported holding MRNS - Marinus Pharmaceuticals, Inc. - Common Stock as of Q2 2023.
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) has 104 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.7M shares
of 54.7M outstanding shares and own 81.6% of the company stock.
Largest 10 shareholders include SUVRETTA CAPITAL MANAGEMENT, LLC (4.06M shares), BlackRock Inc. (3.9M shares), EVENTIDE ASSET MANAGEMENT, LLC (3.17M shares), Avoro Capital Advisors LLC (3.15M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.73M shares), VANGUARD GROUP INC (2.55M shares), Lion Point Capital, LP (2.26M shares), Bleichroeder LP (1.87M shares), JENNISON ASSOCIATES LLC (1.87M shares), and GMT CAPITAL CORP (1.55M shares).
This table shows the top 104 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.